Natera, Inc. reported first quarter ended March 31, 2026 results: revenue $696.6 million, net income $85.1 million, EPS ($0.60) per diluted share. Guidance raised.
“in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights • Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. • Generated a gross margin 1 of 64.7% in the first quarter of 2026,”
Monica Bertagnolli was appointed as member of the Board at Natera, Inc..
“appointed Monica Bertagnolli as a member of the Board, in each case effective as of March 6, 2025.”
Earnings Releases
Natera, Inc. reported first quarter ended March 31, 2024 results: revenue $367.7 million, net income net loss of $67.6 million, EPS ($0.56) per diluted share.
“First Quarter Ended March 31, 2024 Financial Results Total revenues were $367.7 million in the first quarter of 2024 compared to $241.8 million in the first quarter of 2023, an increase of 52.1%. The increase in total revenues was driven primarily by a 53.4% increase in product revenues, which were $364.7 million in the first quarter of 2024 compared to $237.8 million in the first quarter of 2023. The increase in product revenues was primarily driven by an increase in volume, as well as average selling price improvements. Natera processed approximately 735,800 tests in the first quarter of 2024, including approximately 718,700 tests accessioned in its laboratory, compared to approximately 626,200 tests processed, including approximately 607,700 tests accessioned in its laboratory, in the first quarter of 2023. In the first quarter of 2024, Natera recognized revenue on approximately 679,400 tests for which results were reported to customers in the period (tests reported), including appr”
Earnings Releases
Natera, Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $311.1 million, net income ($0.65) per diluted share, EPS ($0.65) per diluted share.
“testing , today reported its financial results for the fourth quarter and year ended December 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $311.1 million in the fourth quarter of 2023, compared to $217.3 million in the fourth quarter of 2022, an increase of 43.2%. Product revenues grew 44.3% over the same period. ● Generated total”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.